Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
about
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumabVisceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteasesIncidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
P2860
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Current and emerging strategie ...... risk assessment of dabigatran.
@ast
Current and emerging strategie ...... risk assessment of dabigatran.
@en
type
label
Current and emerging strategie ...... risk assessment of dabigatran.
@ast
Current and emerging strategie ...... risk assessment of dabigatran.
@en
prefLabel
Current and emerging strategie ...... risk assessment of dabigatran.
@ast
Current and emerging strategie ...... risk assessment of dabigatran.
@en
P2860
P921
P356
P1476
Current and emerging strategie ...... -risk assessment of dabigatran
@en
P2093
Christina L Fanola
P2860
P304
P356
10.2147/VHRM.S62595
P407
P5008
P577
2015-05-27T00:00:00Z